Waters (WAT) FY 2025 Conference September 04, 2025 09:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorUdit Batra - President, CEO & DirectorBrandon CouillardGet started. Thanks, everybody, for sticking with us. Good morning. Welcome to the Wells Fargo Healthcare Conference. I'm Brandon Couillard, covering Life Science Tools and Diagnostics.It is a real treat to have Waters with us at the conference this year. Joining us for this conversation, CEO, Udi Batra. Udi, thanks for being here.Udit ...

Financial Data and Key Metrics Changes - The company raised the midpoint of its guidance by 50 basis points, approximately $100 million, despite a slight adjustment in expectations for China [12][13] - Year-to-date order growth is reported at 7%, setting the company up well for midterm aspirations [15] - Gross margin decreased by about 180 basis points year-over-year due to tariff impacts and R&D costs being reclassified [22][24] Business Line Data and Key Metrics Changes - The capital equipment market in the U.S. is described as buoyant, with strong momentum in hospital capital investments, particularly in imaging and ultrasound [8][9] - The company has a record backlog of $21.3 billion, with a healthy book-to-bill ratio of 1.07 times [18] - The company is experiencing a positive shift in Europe, with increasing momentum in hospital capital [10] Market Data and Key Metrics Changes - The Chinese market showed a slight decline in the second quarter, down by low single digits, but better than expected due to backlog conversion [11] - The company is taking a cautious approach to forecasting for China, adjusting guidance slightly for the second half of the year [12] Company Strategy and Development Direction - The company is focused on creating a world where healthcare has no limits, emphasizing the importance of team and culture [6] - Significant investments in R&D have been made, with a series of product launches expected in 2026 that will transform the company [4] - The company aims for mid-single-digit sales growth over the mid-term, supported by new product launches and strategic deals [47][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the hospital capital equipment environment, noting no significant impact from recent Medicaid cuts [59][60] - The company is optimistic about its midterm growth prospects, driven by new product cycles and successful execution on the commercial side [48][56] - Management remains cautious about the Chinese market but is pleased with overall sales growth for the year [51][52] Other Important Information - The company is committed to holding tariff impacts flat year-over-year, which is seen as a significant achievement [26] - The company is focusing on transitioning from standalone hardware to connected platforms and AI-driven solutions in its product portfolio [76] Q&A Session Summary Question: How has the hospital capital equipment environment evolved through 2025? - Management believes the U.S. capital equipment market is buoyant, with strong momentum in hospital capital investments [8] Question: What are the expectations for order growth going forward? - Management advises against overanalyzing one quarter in isolation, emphasizing robust growth over a trailing multi-quarter basis [15] Question: How should investors think about gross margin moving forward? - Management is pleased with margin progress, despite a decrease in Q2 due to tariffs and R&D cost reclassifications [22][24] Question: What are the growth drivers for digital revenue? - The company is making significant investments in AI technologies, which are expected to drive growth in digital revenue [39][41] Question: What is the strategy for the PCS business? - The new leader is focused on accelerating revenue growth and margin improvement, with potential tuck-in acquisitions being evaluated [75]

1 September 2025 | 1:11PM CST United Imaging (688271.SS): Earnings review: 1H25 results in line while China growth beat; TP up to Rmb174; Buy United Imaging released its 1H25 results on Aug 29, 2025. Both its revenue (Rmb6,016mn, +13% yoy) and net profit (Rmb998mn, +5% yoy) were in-line with GSe (Rmb5,887mn/957mn, respectively). Notably, China growth in 1H25 is +11% yoy, implying c.22% yoy growth in 2Q25 per our estimation. Revenue breakdown: From a product perspective, among the company's five product line ...

August 28, 2025 04:55 AM GMT Mindray Bio-Medical | Asia Pacific Earnings Call Takeaways: Deepening Strategy in "Equipment + Digitalization+ Reccurrence" to Drive Sustainability Key Takeaways See our earnings first take Overseas sales to maintain 10%+ CAGR, with EM at 15%+ near term: EM accounts for 70% of overseas revenue and has a similar sales model to China. Mindray has 13.2% share in equipment and 5.4% in IVD in EM, much lower than in China, suggesting ample room to expand. In DM, high-end client penetr ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of a ...

Key Takeaways Thermo Fisher expands pharma, biotech, and biosciences capacity to support global vaccine demand.TMO's new alliances include a Sanofi site acquisition and a Chan Zuckerberg imaging collaboration.Macroeconomic volatility and rising SG&A costs pressured TMO's margins, while competition remained intense.Thermo Fisher Scientific Inc.’s (TMO) recent slew of strategic collaborations reflects its ongoing commitment to sustainable long-term growth. End markets play an important role as well, bolsterin ...

Transcend Plus Ultrasound system in use EPIQ CVx system clinical view Mini 3D TEE transducer clinical view August 27, 2025 Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. ...

JENA, Germany, Aug. 21, 2025 /PRNewswire/ -- ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 uses proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed element of a new CIRRUS software release, that ...

Company Overview - Outset Medical, Inc. is a medical technology company focused on transforming the dialysis experience with innovative technology [3] - The company has developed the Tablo Hemodialysis System, which is FDA-cleared for use in various healthcare settings, from hospitals to home [3] - Tablo integrates water purification and on-demand dialysate production into a single system, enhancing operational efficiency and patient care [3] Market Presence - The Tablo system is trusted by over 1,000 healthcare facilities in the U.S. and has facilitated millions of treatments administered by thousands of nurses [3] - Outset Medical aims to empower healthcare providers to establish in-house dialysis programs, leading to improved operational, clinical, and financial outcomes [3] Upcoming Events - Management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on September 10, 2025, at 7 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the company's investor relations website [2]

Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and the leading supplier of proton therapy solutions for cancer treatment [6] - IBA employs approximately 2,100 people worldwide and is a certified B Corporation, meeting high standards of social and environmental performance [6] - Universitätsklinikum Heidelberg (UKHD) is a leading modern medical center in Europe, dedicated to high-quality patient care and advanced precision medicine, particularly in radiation oncology [7] Contract Details - IBA and UKHD signed a contract for the installation of a ProteusONE compact proton therapy solution at the University campus in Heidelberg, Germany [1] - The contract includes the supply of the ProteusONE system and multi-year operation and maintenance agreements, with the first payment already received [1][3] - UKHD expects to start treating its first patients with the new system in the second half of 2030 [3] Strategic Importance - The acquisition of the ProteusONE system represents a strategic expansion of UKHD's particle therapy program, enhancing access to advanced proton therapy for cancer patients [2] - This investment strengthens UKHD's role as a global reference center for precision radiation oncology, combining scientific excellence with patient-centered innovation [2] - The typical end-user price for a ProteusONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million [4] Leadership Comments - Olivier Legrain, CEO of IBA, expressed pride in collaborating with UKHD, highlighting the differentiation of IBA in the particle therapy field [4] - Prof. Dr. Jürgen Debus, Chairman of the Board at UKHD, noted that integrating IBA's equipment will help UKHD stay updated with the latest proton therapy technologies and increase patient treatment capacity [4]